Related Experiment Video
Updated: Mar 12, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus
Rosa T Artola1, Christos G Mihos1, Orlando Santana1
1From the Department of Orthopedics and Rheumatology, Cambridge Hospital, Harvard Medical School, Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, and the Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, Florida.
Insights
Statins significantly reduced lipids and high-sensitivity C-reactive protein in systemic lupus erythematosus (SLE) patients, suggesting cardiovascular disease prevention benefits. However, statins did not impact SLE Disease Activity Index scores, indicating no effect on disease activity.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) significantly increases cardiovascular mortality risk.
- Statins, used for lipid modulation, may offer anti-inflammatory benefits in SLE.
- Understanding statins' effects in SLE is crucial for cardiovascular disease (CVD) prevention.
Purpose of the Study:
- To compare the effects of statins versus placebo or no statin therapy in SLE patients.
- To evaluate statins' impact on lipid levels, inflammatory markers, and disease activity in SLE.
Main Methods:
- Meta-analysis of eight studies, including five randomized controlled trials.
- Follow-up measures included serum lipids, inflammatory markers, and SLE Disease Activity Index (SLEDAI) scores.
- Mean differences calculated using inverse variance method under fixed or random-effects models.
Main Results:
- Statin therapy significantly reduced total cholesterol, LDL, and high-sensitivity C-reactive protein (hs-CRP).
- No significant changes were observed in HDL or conventional C-reactive protein levels.
- Statin use did not alter the SLEDAI score, indicating no effect on SLE disease activity.
Conclusions:
- Statins effectively reduce lipid profiles and hs-CRP in SLE patients, supporting their role in primary CVD prevention.
- Current evidence does not support the use of statins for modifying SLE disease activity.
- Further research may clarify the broader immunomodulatory effects of statins in SLE.
Objectives:
Systemic lupus erythematosus (SLE) is associated with a significant risk of cardiovascular mortality. The use of statins for lipid modulation and the prevention of cardiovascular disease in this population also may impart pleiotropic anti-inflammatory and immunomodulatory effects. Our aim was to identify studies that compared the use of statins and placebo or no statin therapy in patients with SLE.
Methods:
A meta-analysis was conducted on the follow-up measures of serum lipid levels, inflammatory markers, and disease activity, which was measured using the SLE Disease Activity Index (SLEDAI) score. The mean difference (MD) was calculated by the inverse variance method under a fixed or random-effects model, as appropriate.
Results:
A total of eight studies met our inclusion criteria, including five randomized controlled trials. The total number of patients was 814 (statins 446, placebo/no statins 368), and follow-up ranged from 1 month to 7 years. The total cholesterol (MD -23.48 mg/dL, 95% confidence interval [CI] -34.57 to -12.39, P < 0.0001), low-density lipoprotein (MD -20.7 mg/dL, 95% CI -30.51 to -10.89, P < 0.0001), and high-sensitivity C-reactive protein (MD -0.40 mg/dL, 95% CI -0.64 to -0.16, P = 0.001) levels were significantly reduced by statin therapy. There was no change with statin use in serum levels of high-density lipoprotein and conventional C-reactive protein, and there was no difference in the SLEDAI score.
Conclusions:
The use of statins in SLE reduced the serum lipid and high-sensitivity C-reactive protein levels, which suggests a role for the primary prevention of cardiovascular disease. Statins did not affect the SLEDAI score, and therefore their use for modifying SLE disease activity levels is not presently supported.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:23Atherosclerosis IV: Nursing Management
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow